ABSTRACT
Background Increasing numbers of injured patients taking dabigatran are presenting to trauma centers raising an important clinical question: Does reversal with idarucizumab outweigh potential bleeding risks associated with dabigatran? The purpose of this study was to describe the prevalence of idarucizumab administration in trauma patients and compare outcomes for those who received reversal to those who did not.
Methods This retrospective cohort study included trauma inpatients >18 years on preinjury dabigatran. Patients were sourced from the registries of Level I–IV trauma centers with an arrival date 1/2017–12/2021. Preinjury dabigatran therapy and idarucizumab administration were confirmed via EMR chart review. Patients on preinjury dabigatran were grouped according to administration status of idarucizumab.
Results 942 trauma patients on preinjury dabigatran (49.7% male; mean GCS:15; >70 years: 85.7%) were included, with 10.8% patients reversed with idarucizumab. No statistically significant differences were found for preinjury dabigatran dose (p=0.703), age (p=0.494), blunt injury type (p=0.070), or mechanism of injury (p=0.248). Those reversed with idarucizumab had a greater median head AIS score (3 vs 2; p<0.001), higher proportion full trauma activations (16.7 vs 8.7%; p=0.019), higher median ISS (10 vs 9; p<0.001), were more likely to have a GCS 3–8 (4.9% vs 0.8%; p=0.006), and had increased rates of blood transfusion (4.9% vs 1.3%; p=0.022), ventilator use (10.8% vs 4.7%,p=0.009), and mortality (expired+hospice) (10.8% vs 4.9%; p=0.021). There was no difference between groups for thromboembolic events (1.0% vs 0.7%; p=0.553), hospital LOS (3 vs 4 days; p=0.147), or ICU LOS (3 vs 3 days; p=0.714).
Conclusions In this large, retrospective cohort study of trauma patients, only 10.8% had reversal with idarucizumab. Patients reversed were more severely injured, with increased ICU and ventilator use, more transfusions ≤24 hours, and had increased mortality compared to those not reversed. There was no difference in thromboembolic events between groups. These findings suggest clinicians may be administering idarucizumab based on injury severity – especially head trauma – regardless of other variables, such as comorbidities. Additional research is needed to determine the optimal role of reversal with idarucizumab vs. other strategies for injured patients on dabigatran.
What is new?
Trauma patients on preinjury dabigatran reversed with idarucizumab were more severely injured and utilized more hospital resources (including increased intensive care unit length of stay and ventilator days) than those not reversed.
There was no difference in thromboembolic events recorded between trauma patients administered idarucizumab compared to those who were not; however, reversal with idarucizumab was associated with increased rates of blood transfusion and total mortality (expired + hospice).
What are the clinical implications?
These findings suggest clinicians may be administering idarucizumab to trauma patients based primarily on injury severity, especially head trauma, regardless of other variables, such as comorbidities.
A large, prospective randomized study of trauma inpatients on preinjury dabigatran that compares dabigatran reversal with idarucizumab to non-specific reversal agents is warranted to establish appropriate criteria for utilization of idarucizumab.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors have no conflicts of interest to declare. All co-authors have seen and agree with the contents of the manuscript and there are no financial interests to report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board (IRB) of the University of Tennessee Health Science Center waived ethical approval for this work and determined it to be exempt from IRB oversight.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
AUTHOR AFFILIATION: This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare affiliated entity. The views expressed in this publication represent those of the authors and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities.
MEETING PRESENTATION: This work was presented as a poster presentation at the Annual Midyear Clinical Meeting and Exhibition of the American Society of Health-System Pharmacists in Las Vegas, Nevada, on December 7, 2022.
ICMJE AUTHORSHIP CONTRIBUTIONS:
RLM: Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project Administration RJW: Methodology, Investigation, Writing - Original Draft, Writing - Review & Editing, Project Administration JJ: Software, Validation, Formal Analysis, Investigation, Data Curation, Writing - Original Draft, Writing - Review & Editing, Visualization SMF: Conceptualization, Methodology, Investigation, Writing - Review & Editing, Supervision, Visualization, Project Administration NYW: Methodology, Investigation, Writing - Review & Editing, Visualization JMG: Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project Administration
rebecca.moore2{at}hcahealthcare.com; ransom.wyse{at}hcahealthcare.com; justin.jacobs{at}hcahealthcare.com; Samir.fakhry{at}hcahealthcare.com; nina.yoes{at}hcahealthcare.com; jenny.garland{at}hcahealthcare.com
Data Availability
The authors had full access to all data in the study and take responsibility for the integrity of the data and accuracy of the data analysis.
NON-STANDARD ABBREVIATIONS AND ACRONYMS
- DOAC
- direct oral anticoagulants
- FDA
- Food and Drug Administration
- DVT
- deep vein thrombosis
- PE
- pulmonary embolism
- TBI
- traumatic brain injury
- NSTEMI
- non-ST elevation myocardial infarction
- ED
- emergency department
- MOI
- mechanism of injury
- ICD-10-CM
- International Classification of Diseases, Tenth Revision, Clinical Modification
- EMR
- electronic medical record
- MAR
- medication administration record
- EDW
- electronic data warehouse
- ICU
- intensive care unit
- LOS
- length of stay, reported in days
- IRB
- institutional review board
- STROBE
- Strengthening the Reporting of Observational Studies in Epidemiology
- ISS
- injury severity score
- IQR
- interquartile range
- GCS
- Glasgow Coma Score
- AIS
- abbreviated injury score
